<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01789255</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2013-00355</org_study_id>
    <secondary_id>NCI-2013-00355</secondary_id>
    <secondary_id>HUM00070080</secondary_id>
    <secondary_id>UMCC 2012.047</secondary_id>
    <secondary_id>9330</secondary_id>
    <secondary_id>P30CA046592</secondary_id>
    <nct_id>NCT01789255</nct_id>
  </id_info>
  <brief_title>Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies</brief_title>
  <official_title>A Pilot Trial of Vorinostat Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease Following Unrelated Donor Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot phase II trial studies how well giving vorinostat, tacrolimus, and methotrexate
      works in preventing graft-versus-host disease (GVHD) after stem cell transplant in patients
      with hematological malignancies. Vorinostat, tacrolimus, and methotrexate may be an effective
      treatment for GVHD caused by a bone marrow transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To assess the safety and the feasibility of the addition of vorinostat to tacrolimus and
      methotrexate GVHD prophylaxis.

      SECONDARY OBJECTIVES:

      I. To determine day 100 grades 2-4 acute GVHD. II. To determine 1-year overall survival and
      relapse-free survival. III. To correlate plasma concentrations of inflammatory markers of
      acute GVHD. IV. To correlate protein acetylation in peripheral blood mononuclear cells before
      and after administration of vorinostat.

      OUTLINE:

      Patients receive vorinostat orally (PO) twice daily (BID) on days -10 to 100. Beginning on
      day -3, patients receive tacrolimus intravenously (IV) continuously or PO BID (or
      cyclosporine IV continuously or PO in patients unable to tolerate tacrolimus) with taper on
      days 100-180.Patients also receive methotrexate IV once daily (QD) on days 1, 3, 6, and 11.

      After completion of study treatment, patients are followed up periodically for 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Participants That Experience Grade 2-4 Acute GVHD (Graft Versus Host Disease) by Day 100</measure>
    <time_frame>Day 100</time_frame>
    <description>The incidence of grade 2-4 acute GVHD (Graft Versus Host Disease) by day 100
Grade 2 GVHD: Maculopapular rash covering 25-50% of BSA (Body Surface Area), bilirubin between 3.1-6 mg/dl, and/ or adult stool output between 1000-1500 ml/day (child between 20-30 ml/kg/day).
Grade 3 GVHD: Maculopapular rash covering &gt;50% of BSA, bilirubin between 6.1-15 mg/dl, and/ or adult stool output &gt;1500 ml/day (child &gt;30 ml/kg/day).
Grade 4 GVHD: Generalized erythroderma plus bullous formation and desquamation &gt;5% BSA, bilirubin &gt;15 mg/dl, and/ or severe abdominal pain with or without ileus, or grossly bloody stool.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Percent of Planned Dose Administered</measure>
    <time_frame>Up to day 30</time_frame>
    <description>The addition of vorinostat to tacrolimus and methotrexate for GVHD prophylaxis will be considered feasible if 60% or more of the planned doses are administered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steroid-free Survival</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Estimated with Kaplan-Meier methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Estimated with Kaplan-Meier methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Estimated with Kaplan-Meier methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histone Acetylation in Peripheral Blood Stem Cells (PBMC)</measure>
    <time_frame>Up to day 100</time_frame>
    <description>Summarized with means and 95% confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations of Inflammatory GVHD Markers</measure>
    <time_frame>Up to day 100</time_frame>
    <description>Summarized with means and 95% confidence intervals.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Accelerated Phase Chronic Myelogenous Leukemia</condition>
  <condition>Adult Acute Myeloid Leukemia in Remission</condition>
  <condition>Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities</condition>
  <condition>Adult Acute Myeloid Leukemia With Del(5q)</condition>
  <condition>Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)</condition>
  <condition>Adult Grade III Lymphomatoid Granulomatosis</condition>
  <condition>B-cell Chronic Lymphocytic Leukemia</condition>
  <condition>Chronic Myelogenous Leukemia, BCR-ABL1 Positive</condition>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <condition>Chronic Phase Chronic Myelogenous Leukemia</condition>
  <condition>Contiguous Stage II Adult Burkitt Lymphoma</condition>
  <condition>Contiguous Stage II Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma</condition>
  <condition>Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma</condition>
  <condition>Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma</condition>
  <condition>Contiguous Stage II Adult Lymphoblastic Lymphoma</condition>
  <condition>Contiguous Stage II Grade 1 Follicular Lymphoma</condition>
  <condition>Contiguous Stage II Grade 2 Follicular Lymphoma</condition>
  <condition>Contiguous Stage II Grade 3 Follicular Lymphoma</condition>
  <condition>Contiguous Stage II Mantle Cell Lymphoma</condition>
  <condition>Contiguous Stage II Marginal Zone Lymphoma</condition>
  <condition>Contiguous Stage II Small Lymphocytic Lymphoma</condition>
  <condition>Cutaneous B-cell Non-Hodgkin Lymphoma</condition>
  <condition>Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue</condition>
  <condition>Graft Versus Host Disease</condition>
  <condition>Intraocular Lymphoma</condition>
  <condition>Myelodysplastic Syndrome With Isolated Del(5q)</condition>
  <condition>Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable</condition>
  <condition>Nodal Marginal Zone B-cell Lymphoma</condition>
  <condition>Noncontiguous Stage II Adult Burkitt Lymphoma</condition>
  <condition>Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma</condition>
  <condition>Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma</condition>
  <condition>Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma</condition>
  <condition>Noncontiguous Stage II Adult Lymphoblastic Lymphoma</condition>
  <condition>Noncontiguous Stage II Grade 1 Follicular Lymphoma</condition>
  <condition>Noncontiguous Stage II Grade 2 Follicular Lymphoma</condition>
  <condition>Noncontiguous Stage II Grade 3 Follicular Lymphoma</condition>
  <condition>Noncontiguous Stage II Mantle Cell Lymphoma</condition>
  <condition>Noncontiguous Stage II Marginal Zone Lymphoma</condition>
  <condition>Noncontiguous Stage II Small Lymphocytic Lymphoma</condition>
  <condition>Post-transplant Lymphoproliferative Disorder</condition>
  <condition>Primary Central Nervous System Hodgkin Lymphoma</condition>
  <condition>Primary Central Nervous System Non-Hodgkin Lymphoma</condition>
  <condition>Recurrent Adult Acute Myeloid Leukemia</condition>
  <condition>Recurrent Adult Burkitt Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Mixed Cell Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Small Cleaved Cell Lymphoma</condition>
  <condition>Recurrent Adult Grade III Lymphomatoid Granulomatosis</condition>
  <condition>Recurrent Adult Hodgkin Lymphoma</condition>
  <condition>Recurrent Adult Immunoblastic Large Cell Lymphoma</condition>
  <condition>Recurrent Adult Lymphoblastic Lymphoma</condition>
  <condition>Recurrent Grade 1 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 2 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 3 Follicular Lymphoma</condition>
  <condition>Recurrent Mantle Cell Lymphoma</condition>
  <condition>Recurrent Marginal Zone Lymphoma</condition>
  <condition>Recurrent Small Lymphocytic Lymphoma</condition>
  <condition>Refractory Anemia</condition>
  <condition>Refractory Anemia With Excess Blasts</condition>
  <condition>Refractory Anemia With Ringed Sideroblasts</condition>
  <condition>Refractory Chronic Lymphocytic Leukemia</condition>
  <condition>Refractory Cytopenia With Multilineage Dysplasia</condition>
  <condition>Refractory Hairy Cell Leukemia</condition>
  <condition>Relapsing Chronic Myelogenous Leukemia</condition>
  <condition>Secondary Central Nervous System Hodgkin Lymphoma</condition>
  <condition>Secondary Central Nervous System Non-Hodgkin Lymphoma</condition>
  <condition>Small Intestine Lymphoma</condition>
  <condition>Splenic Marginal Zone Lymphoma</condition>
  <condition>Stage I Adult Burkitt Lymphoma</condition>
  <condition>Stage I Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Stage I Adult Diffuse Mixed Cell Lymphoma</condition>
  <condition>Stage I Adult Diffuse Small Cleaved Cell Lymphoma</condition>
  <condition>Stage I Adult Hodgkin Lymphoma</condition>
  <condition>Stage I Adult Immunoblastic Large Cell Lymphoma</condition>
  <condition>Stage I Adult Lymphoblastic Lymphoma</condition>
  <condition>Stage I Chronic Lymphocytic Leukemia</condition>
  <condition>Stage I Grade 1 Follicular Lymphoma</condition>
  <condition>Stage I Grade 2 Follicular Lymphoma</condition>
  <condition>Stage I Grade 3 Follicular Lymphoma</condition>
  <condition>Stage I Mantle Cell Lymphoma</condition>
  <condition>Stage I Marginal Zone Lymphoma</condition>
  <condition>Stage I Small Lymphocytic Lymphoma</condition>
  <condition>Stage II Adult Hodgkin Lymphoma</condition>
  <condition>Stage II Chronic Lymphocytic Leukemia</condition>
  <condition>Stage III Adult Burkitt Lymphoma</condition>
  <condition>Stage III Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Stage III Adult Diffuse Mixed Cell Lymphoma</condition>
  <condition>Stage III Adult Diffuse Small Cleaved Cell Lymphoma</condition>
  <condition>Stage III Adult Hodgkin Lymphoma</condition>
  <condition>Stage III Adult Immunoblastic Large Cell Lymphoma</condition>
  <condition>Stage III Adult Lymphoblastic Lymphoma</condition>
  <condition>Stage III Chronic Lymphocytic Leukemia</condition>
  <condition>Stage III Grade 1 Follicular Lymphoma</condition>
  <condition>Stage III Grade 2 Follicular Lymphoma</condition>
  <condition>Stage III Grade 3 Follicular Lymphoma</condition>
  <condition>Stage III Mantle Cell Lymphoma</condition>
  <condition>Stage III Marginal Zone Lymphoma</condition>
  <condition>Stage IV Adult Burkitt Lymphoma</condition>
  <condition>Stage IV Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Stage IV Adult Diffuse Mixed Cell Lymphoma</condition>
  <condition>Stage IV Adult Diffuse Small Cleaved Cell Lymphoma</condition>
  <condition>Stage IV Adult Hodgkin Lymphoma</condition>
  <condition>Stage IV Adult Immunoblastic Large Cell Lymphoma</condition>
  <condition>Stage IV Adult Lymphoblastic Lymphoma</condition>
  <condition>Stage IV Chronic Lymphocytic Leukemia</condition>
  <condition>Stage IV Grade 1 Follicular Lymphoma</condition>
  <condition>Stage IV Grade 2 Follicular Lymphoma</condition>
  <condition>Stage IV Grade 3 Follicular Lymphoma</condition>
  <condition>Stage IV Mantle Cell Lymphoma</condition>
  <condition>Stage IV Marginal Zone Lymphoma</condition>
  <condition>Stage IV Small Lymphocytic Lymphoma</condition>
  <condition>Testicular Lymphoma</condition>
  <condition>Waldenstr√∂m Macroglobulinemia</condition>
  <arm_group>
    <arm_group_label>Supportive care (vorinostat, tacrolimus, methotrexate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive vorinostat PO BID on days -10 to 100. Beginning on day -3, patients receive tacrolimus IV continuously or PO BID (or cyclosporine IV continuously or PO in patients unable to tolerate tacrolimus) with taper on days 100-180.Patients also receive methotrexate IV QD on days 1, 3, 6, and 11.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vorinostat</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Supportive care (vorinostat, tacrolimus, methotrexate)</arm_group_label>
    <other_name>L-001079038</other_name>
    <other_name>SAHA</other_name>
    <other_name>suberoylanilide hydroxamic acid</other_name>
    <other_name>Zolinza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Supportive care (vorinostat, tacrolimus, methotrexate)</arm_group_label>
    <other_name>FK 506</other_name>
    <other_name>Prograf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Supportive care (vorinostat, tacrolimus, methotrexate)</arm_group_label>
    <other_name>ciclosporin</other_name>
    <other_name>cyclosporin</other_name>
    <other_name>cyclosporin A</other_name>
    <other_name>CYSP</other_name>
    <other_name>Sandimmune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Supportive care (vorinostat, tacrolimus, methotrexate)</arm_group_label>
    <other_name>amethopterin</other_name>
    <other_name>Folex</other_name>
    <other_name>methylaminopterin</other_name>
    <other_name>Mexate</other_name>
    <other_name>MTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Supportive care (vorinostat, tacrolimus, methotrexate)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Supportive care (vorinostat, tacrolimus, methotrexate)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A prospective patient for allogeneic HSCT for hematologic conditions, both malignant
             and non-malignant; donor can be unrelated marrow or peripheral blood cells; a patient
             with history of central nervous system (CNS) involvement is eligible if CNS disease is
             in remission at time of study consideration

          -  The donor and recipient must have a human leukocyte antigen (HLA)-8/8 allelic match at
             the HLA-A, -B, -C, and -DRB1; high-resolution typing is required for all alleles

          -  Diagnoses to be included:

          -  Acute myelogenous leukemia at the following stages:

               -  First remission

               -  Second or subsequent remission

               -  Complete remission is defined as the absence of blasts in the peripheral
                  circulation at the time of enrollment and &lt; 5% blasts in the bone marrow

          -  Chronic myelogenous leukemia at the following stages:

               -  First or subsequent chronic phase:

                    -  Patient refused tyrosine kinase therapy or is otherwise not suited for it

                    -  Stable, not hematologic remission: blasts present in marrow and/or
                       peripheral blood, but disease does not qualify as accelerated or blast phase

                    -  Hematologic remission: no blast cells or precursor cells in the blood or
                       marrow

                    -  Partial cytogenetic remission: Philadelphia chromosome positive (Ph+)
                       metaphases &gt; 0% but &lt; 35%

                    -  Complete cytogenetic remission: absence of Ph+ metaphases

               -  Accelerated phase - any one of the following symptoms:

                    -  White blood cells (WBC) difficult to control (&gt; 50 x 10^9/L despite therapy)

                    -  Rapid doubling of WBC (&lt; 5 days)

                    -  10% blasts in blood or marrow

                    -  20% blasts and/or promyelocytes in blood or marrow

                    -  20% basophils and/or eosinophils in blood

                    -  Anemia or thrombocytopenia unresponsive to standard treatment

                    -  Persistent thrombocytosis (&gt; 1000 x 10^9/L)

                    -  Cytogenetic abnormalities in addition to Ph+

                    -  Increasing splenomegaly

                    -  Marrow fibrosis

          -  Myelodysplastic syndromes at any of the following stages:

               -  Refractory anemia

               -  Refractory anemia with ringed sideroblasts

               -  Refractory cytopenia with multilineage dysplasia

               -  Refractory cytopenia with multilineage dysplasia and ringed sideroblasts

               -  Refractory anemia with excess blasts-1 (5-10% blasts)

               -  Refractory anemia with excess blasts-2 (10-20% blasts)

               -  Myelodysplastic syndrome, unclassified

               -  Myelodysplastic syndrome (MDS) associated with isolated del (5q)

               -  Chronic myelomonocytic leukemia

          -  Primary Myelofibrosis

               -  Intermediate-2 risk or high risk disease

               -  Patients should have extinguished standard of care options prior to being
                  considered for this trial

          -  Chronic lymphocytic leukemia

               -  Complete remission: the disease is completely absent and no relapse occurred
                  prior to the preparative regimen; requires all of the following:

                    -  Nodular partial remission: complete response with persistent lymphoid
                       nodules in bone marrow

                    -  Partial remission: reduction of more than 50% in the disease burden
                       regardless of the number of lines of therapy received

          -  Mature B cell malignancies

               -  Patients should have extinguished standard of care options prior to being
                  considered eligible for this trial

               -  First complete remission (CR1) confirmed: complete disappearance of all known
                  disease; the term &quot;confirmed&quot; is defined as a laboratory and/or pathological or
                  radiographic determination.

               -  CR1 unconfirmed (CRU1): complete disappearance of all known disease with the
                  exception of persistent scan abnormalities of unknown significance; the term
                  &quot;unconfirmed&quot; is defined as scan abnormalities of unknown significance that are
                  not biopsied or otherwise evaluated

               -  Second or subsequent complete remission (CR2+) confirmed: the recipient relapsed,
                  then achieved complete absence of disease without radiographic evidence of
                  disease

               -  CR2+ unconfirmed: the recipient has achieved a second or subsequent complete
                  response but has persistent radiographic abnormalities of unknown significance.

               -  Partial remission: reductions of &gt;= 50% in greatest diameter of all sites of
                  known disease and no new sites

          -  Karnofsky &gt;= 70%

          -  Life expectancy of greater than 6 months

          -  Total bilirubin =&lt; 2.5 mg% (unless from Gilbert's disease or disease-related)

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
             &lt; 3.0 X institutional upper limit of normal

          -  Estimated or actual glomerular filtration rate (GFR) &gt; 50 mL/min/1.73 m^2 for patients
             with creatinine levels above institutional normal; GFR should be corrected for body
             surface area (BSA)

          -  Diffusing capacity of the lung for carbon monoxide (DLCO) &gt; 50%; DLCO should be
             corrected for hemoglobin

          -  Forced expiratory volume in 1 second (FEV1) &gt; 50%

          -  Forced vital capacity (FVC) &gt; 50%

          -  Ejection fraction &gt;= 50%

          -  The effects of vorinostat on the developing human fetus are unknown; for this reason
             and because histone deacetylase inhibitor agents as well as other therapeutic agents
             used in this trial (e.g., tacrolimus and methotrexate) are known to be teratogenic,
             women of child-bearing potential and men must agree to use adequate contraception
             (hormonal or barrier method of birth control; abstinence) prior to study entry and for
             the duration of study participation; should a woman become pregnant or suspect she is
             pregnant while she or her partner is participating in this study, she should inform
             her treating physician immediately; men treated or enrolled on this protocol must also
             agree to use adequate contraception prior to the study, for the duration of study
             participation, and 4 months after completion of vorinostat administration

          -  Ability to understand and the willingness to sign a written informed consent document

          -  Patients must be able to swallow capsules/tablets

        Exclusion Criteria:

          -  Patients who are not a candidate for an unrelated donor allogeneic HSCT based on the
             current institutional bone marrow transplant (BMT) program clinical practice
             guidelines; organ function criteria will be utilized per the current institutional BMT
             program clinical practice guidelines; there will be no restriction to study entry
             based on hematological parameters

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to vorinostat

          -  Patients undergoing a total body irradiation (TBI)-based conditioning regimen (TBI
             1200 centigray [cGy])

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements; patients still under therapy for presumed or proven infection are
             eligible provided there is clear evidence (radiographic findings and/or culture
             results) that the infection is well-controlled; patients under treatment for infection
             will be enrolled only after clearance from the Principal Investigator (PI)

          -  Pregnant women are excluded from this study because vorinostat is a histone
             deacetylase inhibitor agent with the potential for teratogenic or abortifacient
             effects; because there is an unknown but potential risk for adverse events in nursing
             infants secondary to treatment of the mother with vorinostat, breastfeeding should be
             discontinued if the mother is treated with vorinostat

          -  Patients with evidence of human immunodeficiency virus (HIV) seropositivity and/or
             positive polymerase chain reaction (PCR) assay, human T-lymphotropic virus
             (HTLV)1/HTLV2 seropositivity; the safety of allogeneic HSCT is not yet
             well-established for this population

          -  Patients with evidence of hepatitis B or hepatitis C PCR positivity; hepatitis
             reactivation following myelosuppressive therapy can lead to fatal complications

          -  Patients with a history of prolonged corrected QT interval (QTc) syndrome

          -  Patients asking or who have had prior treatment with a drug like vorinostat (i.e.,
             valproic acid) within the last 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pavan Reddy</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan University Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2013</study_first_submitted>
  <study_first_submitted_qc>February 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2013</study_first_posted>
  <results_first_submitted>August 26, 2015</results_first_submitted>
  <results_first_submitted_qc>October 13, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 13, 2015</results_first_posted>
  <last_update_submitted>October 13, 2015</last_update_submitted>
  <last_update_submitted_qc>October 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Burkitt Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Immunoblastic</mesh_term>
    <mesh_term>Plasmablastic Lymphoma</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Anemia, Refractory</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Leukemia, Hairy Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
    <mesh_term>Lymphomatoid Granulomatosis</mesh_term>
    <mesh_term>Lymphoproliferative Disorders</mesh_term>
    <mesh_term>Lymphoma, Extranodal NK-T-Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid, Accelerated Phase</mesh_term>
    <mesh_term>Anemia, Refractory, with Excess of Blasts</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Intraocular Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Vorinostat</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Supportive Care (Vorinostat, Tacrolimus, Methotrexate)</title>
          <description>Patients receive vorinostat PO BID on days -10 to 100. Beginning on day -3, patients receive tacrolimus IV continuously or PO BID (or cyclosporine IV continuously or PO in patients unable to tolerate tacrolimus) with taper on days 100-180. Patients also receive methotrexate IV QD on days 1, 3, 6, and 11.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Supportive Care (Vorinostat, Tacrolimus, Methotrexate)</title>
          <description>Patients receive vorinostat PO BID on days -10 to 100. Beginning on day -3, patients receive tacrolimus IV continuously or PO BID (or cyclosporine IV continuously or PO in patients unable to tolerate tacrolimus) with taper on days 100-180. Patients also receive methotrexate IV QD on days 1, 3, 6, and 11.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" lower_limit="45" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of Participants That Experience Grade 2-4 Acute GVHD (Graft Versus Host Disease) by Day 100</title>
        <description>The incidence of grade 2-4 acute GVHD (Graft Versus Host Disease) by day 100
Grade 2 GVHD: Maculopapular rash covering 25-50% of BSA (Body Surface Area), bilirubin between 3.1-6 mg/dl, and/ or adult stool output between 1000-1500 ml/day (child between 20-30 ml/kg/day).
Grade 3 GVHD: Maculopapular rash covering &gt;50% of BSA, bilirubin between 6.1-15 mg/dl, and/ or adult stool output &gt;1500 ml/day (child &gt;30 ml/kg/day).
Grade 4 GVHD: Generalized erythroderma plus bullous formation and desquamation &gt;5% BSA, bilirubin &gt;15 mg/dl, and/ or severe abdominal pain with or without ileus, or grossly bloody stool.</description>
        <time_frame>Day 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Supportive Care (Vorinostat, Tacrolimus, Methotrexate)</title>
            <description>Patients receive vorinostat PO BID on days -10 to 100. Beginning on day -3, patients receive tacrolimus IV continuously or PO BID (or cyclosporine IV continuously or PO in patients unable to tolerate tacrolimus) with taper on days 100-180. Patients also receive methotrexate IV QD on days 1, 3, 6, and 11.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants That Experience Grade 2-4 Acute GVHD (Graft Versus Host Disease) by Day 100</title>
          <description>The incidence of grade 2-4 acute GVHD (Graft Versus Host Disease) by day 100
Grade 2 GVHD: Maculopapular rash covering 25-50% of BSA (Body Surface Area), bilirubin between 3.1-6 mg/dl, and/ or adult stool output between 1000-1500 ml/day (child between 20-30 ml/kg/day).
Grade 3 GVHD: Maculopapular rash covering &gt;50% of BSA, bilirubin between 6.1-15 mg/dl, and/ or adult stool output &gt;1500 ml/day (child &gt;30 ml/kg/day).
Grade 4 GVHD: Generalized erythroderma plus bullous formation and desquamation &gt;5% BSA, bilirubin &gt;15 mg/dl, and/ or severe abdominal pain with or without ileus, or grossly bloody stool.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent of Planned Dose Administered</title>
        <description>The addition of vorinostat to tacrolimus and methotrexate for GVHD prophylaxis will be considered feasible if 60% or more of the planned doses are administered.</description>
        <time_frame>Up to day 30</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Supportive Care (Vorinostat, Tacrolimus, Methotrexate)</title>
            <description>Patients receive vorinostat PO BID on days -10 to 100. Beginning on day -3, patients receive tacrolimus IV continuously or PO BID (or cyclosporine IV continuously or PO in patients unable to tolerate tacrolimus) with taper on days 100-180. Patients also receive methotrexate IV QD on days 1, 3, 6, and 11.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent of Planned Dose Administered</title>
          <description>The addition of vorinostat to tacrolimus and methotrexate for GVHD prophylaxis will be considered feasible if 60% or more of the planned doses are administered.</description>
          <units>percent of dose administered</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.5" lower_limit="53.8" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Steroid-free Survival</title>
        <description>Estimated with Kaplan-Meier methods.</description>
        <time_frame>Up to 1 year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Estimated with Kaplan-Meier methods.</description>
        <time_frame>Up to 1 year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relapse</title>
        <description>Estimated with Kaplan-Meier methods.</description>
        <time_frame>Up to 1 year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Histone Acetylation in Peripheral Blood Stem Cells (PBMC)</title>
        <description>Summarized with means and 95% confidence intervals.</description>
        <time_frame>Up to day 100</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentrations of Inflammatory GVHD Markers</title>
        <description>Summarized with means and 95% confidence intervals.</description>
        <time_frame>Up to day 100</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Supportive Care (Vorinostat, Tacrolimus, Methotrexate)</title>
          <description>Patients receive vorinostat PO BID on days -10 to 100. Beginning on day -3, patients receive tacrolimus IV continuously or PO BID (or cyclosporine IV continuously or PO in patients unable to tolerate tacrolimus) with taper on days 100-180. Patients also receive methotrexate IV QD on days 1, 3, 6, and 11.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Immune system disorders, Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified, Other</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Immune system disorders, Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified, Other</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pavan Reddy, M.D.</name_or_title>
      <organization>University of Michigan Comprehensive Cancer Center</organization>
      <phone>734-647-5954</phone>
      <email>reddypr@umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

